Skip to main content
INKON Life Technology Co., Ltd. logo

INKON Life Technology Co., Ltd. — Investor Relations & Filings

Ticker · 300143 ISIN · CNE100000XF6 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,851 across all filing types
Latest filing 2024-10-27 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300143

About INKON Life Technology Co., Ltd.

https://www.inkonlife.com

INKON Life Technology Co., Ltd. specializes in the development and manufacture of advanced medical equipment and digital healthcare solutions. The company focuses on two primary sectors: radiotherapy equipment and digital medical services. Its core product portfolio includes high-precision radiotherapy systems, such as the Gamma Knife, and medical infusion systems. INKON Life leverages Internet of Things (IoT) technology to provide integrated digital hospital solutions, aiming to improve clinical efficiency and patient outcomes. The company serves oncology centers and medical institutions by providing comprehensive cancer treatment solutions and smart healthcare management platforms. By combining medical engineering with digital innovation, INKON Life focuses on the modernization of radiotherapy and the digital transformation of healthcare delivery.

Recent filings

Filing Released Lang Actions
第六届董事会第十一次（临时）会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the company's sixth board of directors' eleventh (extraordinary) meeting. It includes details about the meeting's convening, attendance, and voting results on specific agenda items such as approval of the 2024 third quarter report and related party transactions. The document does not contain the full quarterly report itself but references that the full report is disclosed elsewhere (on the cninfo website). The document is relatively short (1339 characters) and serves as a meeting resolution announcement rather than a full financial report. This fits the category of Board/Management Information (MANG), which covers announcements of board decisions and management matters.
2024-10-27 Chinese
国泰君安证券股份有限公司关于盈康生命科技股份有限公司向特定对象发行股票发行过程和认购对象合规性的报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Guotai Junan Securities Co., Ltd. acting as the sponsor and lead underwriter for Yingkang Life Technology Co., Ltd.'s private placement of shares to a specific investor. It includes comprehensive information about the issuance process, compliance with relevant laws and regulations, pricing, subscription details, approval procedures, regulatory approvals, and verification of funds. The document is titled as a report on the issuance process and compliance of the subscription objects, indicating it is a formal compliance and process report rather than a simple announcement or a financial statement. It is not an annual or interim report, earnings release, or a proxy statement. It is not a regulatory filing or announcement of a report but a substantive report on the issuance process and compliance. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2024-10-23 Chinese
盈康生命科技股份有限公司向特定对象发行股票认购资金到位情况验证报告
Audit Report / Information Classification · 95% confidence The document is a verification report issued by an accounting firm regarding the subscription funds received for a specific private placement of shares by 盈康生命科技股份有限公司 (Yingkang Life Technology Co., Ltd.). It details the amount of funds received, the approval by regulatory bodies including the China Securities Regulatory Commission (CSRC), and the compliance with shareholder and board resolutions. The document includes a verification opinion on the subscription funds being in place as of a specific date, along with detailed attachments showing the subscription amounts and verification matters. This type of document is a standalone audit or verification report related to a capital raising event, specifically verifying the receipt of subscription funds for a private placement. It is not an annual or interim report, nor a general announcement or presentation. It is not a regulatory filing or announcement of a report but the actual verification report itself. Therefore, the appropriate classification is Audit Report / Information (AR). The document length (6854 characters) supports it being a full report rather than a brief announcement. Q4 2024
2024-10-23 Chinese
北京市金杜律师事务所关于青岛盈康医疗投资有限公司免于发出要约事宜的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding a specific stock issuance by a company to a particular investor. It discusses the legal qualifications of the investor, approvals and authorizations for the issuance, and compliance with regulatory requirements related to exemption from making a tender offer. The document references specific laws and regulations, shareholder meeting approvals, and regulatory filings but does not contain financial statements or detailed financial performance data. It is a standalone legal opinion related to a capital issuance event, not the issuance announcement itself or a full financial report. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (5772 characters) and content confirm it is a substantive legal opinion rather than a brief announcement or certification, supporting this classification with high confidence.
2024-10-23 Chinese
盈康生命科技股份有限公司向特定对象发行股票募集资金验资报告
Audit Report / Information Classification · 95% confidence The document is a detailed verification report (验资报告) issued by an accounting firm regarding the capital increase through a private placement of shares by 盈康生命科技股份有限公司. It includes specifics about the issuance of new shares, the amount of capital raised, the changes in registered capital and share capital, and the approval from the China Securities Regulatory Commission (CSRC). The document contains detailed financial and capital structure data, audit opinions, and attachments related to the capital increase. This is a standalone audit/verification report related to the capital raising activity, not a full annual or interim report, nor a simple announcement. It fits the definition of an Audit Report / Information (AR) as it is a verification report on the capital increase and issuance of shares, including audit procedures and results, but not a full annual report or earnings release. FY 2024
2024-10-23 Chinese
北京市金杜律师事务所关于盈康生命科技股份有限公司向特定对象发行股票发行过程和认购对象合规性的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding a company's private placement of shares to specific investors. It details the approval process, board and shareholder resolutions, regulatory approvals, subscription agreements, pricing, payment, and verification of funds. The document is focused on the issuance of shares and compliance with securities laws and regulations. It is not a financial report, earnings release, or management discussion. It is a legal opinion related to a capital raising event, specifically a private placement of shares. Therefore, the document fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2024-10-23 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.